HilleVax

Focused on the development and commercialization of novel vaccines

HilleVax is a Frazier-founded company focused on the development and commercialization of novel vaccine candidates. The company has licensed rights from Takeda to develop and commercialize its norovirus vaccine candidate worldwide outside of Japan. HIL-214 is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Status
IPO in 2022 (NASDAQ: HLVX)
Year of Investment
2021
Strategy
Life Sciences
Location
Boston, Massachusetts